SCHEMBL6492289

SCHEMBL6492289

c1ccc2cc3cc(NCc4ccncc4)ccc3cc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INSR P06213 1/20 0.53
IGF1R P08069 1/20 0.53
KCNH3 Q9ULD8 1/20 0.51
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 5/20 0.51
GAA P10253 3/20 0.51
MAPT P10636 3/20 0.51
HSD17B10 Q99714 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
PABPC1 P11940 1/20 0.51
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
HIF1A Q16665 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
MEN1 O00255 1/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542592 0.80 MRGPRX4 (0.67) INSRIGF1RALDH1A1KDM4EGAA
SCHEMBL19242049 0.78 KDM4E (0.61) KCNH3ALDH1A1KDM4EGAAMAPT
SCHEMBL20036943 0.77 INSR (0.75) INSRIGF1RALDH1A1HSD17B10CYP1A2
SCHEMBL28014135 0.76 FLT1 (0.65) ALDH1A1KDM4EGAAMAPTCYP1A2
SCHEMBL522061 0.76 KCNH3 (0.68) KCNH3CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL30436961 0.75 INSR (0.62) INSRIGF1RKCNH3ALDH1A1KDM4E
SCHEMBL21036095 0.75 HTT (0.62) INSRIGF1RALDH1A1KDM4EGAA
SCHEMBL6528948 0.74 KDM4E (0.64) KCNH3ALDH1A1KDM4EGAAMAPT
SCHEMBL6494751 0.74 ATM (0.57) INSRIGF1RMRGPRX4
SCHEMBL19241691 0.73 F2 (0.56) KCNH3ALDH1A1KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 INSR 4011/4885IGF1R 3806/4885KCNH3 354/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 INSR 2847/4885IGF1R 2250/4885KCNH3 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.